Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtezoTRIBE first-line metastatic colorectal cancer trial
2017-000977-35Phase 2Completed
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing FOLFOXIRI + bevacizumab + atezolizumab with FOLFOXIRI + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
atezolizumabbevacizumabFOLFIRINOX
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-000977-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000977-35.